Hyperlipidaemia is present in only half of all patients who develop coronary heart disease. Over the past several years evidence has accumulated that inflammatory mechanisms play a pivotal role in the genesis of atherosclerosis and its complications [1] . Attention has thus focused on whether circulating markers of inflammation can provide a new method to improve cardiovascular risk prediction. These markers include high sensitivity C-reactive protein, serum amyloid A, interleukin-6, heat shock protein 65 and soluble intercellular adhesion molecule type 1 [2] [3] [4] [5] [6] [7] [8] .
Of these inflammatory markers, high sensitivity C-reactive protein has been the best studied. Produced in the liver in response to interleukin-6, high sensitivity C-reactive protein has been shown to predict myocardial infarction, stroke and vascular death in a variety of clinical settings [2] [3] [4] [5] 9, 10] . High sensitivity C-reactive protein also appears to have predictive value in both stable and unstable angina as well as in the chronic phase after myocardial infarction [11] [12] [13] [14] [15] , an intriguing finding in light of the emerging role of inflammation in determining plaque stability [16] . Lack of standardization of assays, inconsistency of prospective data and concern about variation in levels have led to doubts regarding the clinical utility of inflammatory markers [17] . Also, data supporting the hypothesis, that inflammatory markers could improve upon traditional lipid screening, are few and mainly derived from studies of C-reactive protein in middle-aged men [4, 5, 10] . A recent analysis from the Women's Health Study sought to address these issues [18] . This prospective, nested case-control study among 28 263 apparently healthy post-menopausal women sought to determine the risk of cardiovascular events associated with baseline levels of a variety of inflammatory and other markers. Incident cardiovascular events included death from coronary heart disease, non-fatal myocardial infarction or stroke, or the need for coronary revascularization procedures. The mean follow-up period was 3 years and the markers assessed at baseline included high sensitivity C-reactive protein, serum amyloid A, interleukin-6, sICAM-1, homocysteine, and several traditional lipid and lipoprotein parameters.
Levels of all four inflammatory markers were significantly elevated at baseline in the women who subsequently developed cardiovascular events compared to those who did not. Similarly, levels of homocysteine, total cholesterol, LDL cholesterol, apolipoprotein B-100 and the ratio of total cholesterol to HDL cholesterol were significantly higher among women with subsequent events.
However, of all the measures, high sensitivity C-reactive protein was the single most powerful predictor of risk by univariate analysis (relative risk for those in the highest compared with the lowest quartile, 4·4; 95% confidence interval, 2·2 to 8·9; P<0·001). Of the lipid parameters, the ratio of total cholesterol to HDL cholesterol (relative risk 3·4; P=0·001) and apolipoprotein B-100 level (relative risk 3·4; P=0·001) were the most powerful predictors. Correlations between inflammatory markers and lipid parameters were low, with less than 10% of the variance in any marker of inflammation being explained by any lipid measure. Multivariate analysis found only the level of high sensitivity C-reactive protein and the ratio of total cholesterol to HDL cholesterol to be independent predictors of risk in models where women were matched for age and smoking status or in further models where additional adjustments for body-mass index, hypertension, diabetes and parental history of premature coronary heart disease were made.
To explore whether any of the markers of inflammation added to the predictive value of lipid-based screening, additional analyses were performed. First, the study participants were stratified into groups according to total cholesterol level and the level of high sensitivity C-reactive protein; even women with low total cholesterol levels were found to be at significantly higher risk when the level of high sensitivity C-reactive protein was high. These associations were also present for serum amyloid A but to a lesser extent for interleukin-6 and sICAM-1.
Second, likelihood-ratio tests, used to compare the fit of predictive models based on an inflammatory marker in combination with lipids to the fit based on lipid measurements alone, showed that each of the markers of inflammation significantly improved the usefulness of lipid screening in predicting risk. For example, models involving high sensitivity C-reactive protein and the ratio of total cholesterol to HDL cholesterol significantly improved prediction when compared with models based solely on the ratio of total cholesterol to HDL cholesterol (P<0·001). These effects were additive across all lipid levels and across all strata of high sensitivity C-reactive protein (Fig. 1) .
Finally, a subgroup analysis was performed on the women with LDL <130 mg . dl 1 , the current target for primary prevention of the National Cholesterol Education Program [19] . The mean LDL for this subgroup was 104 mg . dl 1 . In this analysis, women with increased baseline levels of markers of inflammation were found to be at increased risk for subsequent cardiovascular events. This effect was strongest for high sensitivity C-reactive protein; specifically the relative risks for increasing quartiles of high sensitivity C-reactive protein in this subgroup were 1·0, 2·4, 2·9 and 4·1 (95% confidence interval for highest as compared to lowest quartile 1·7 to 11·3; P=0·002). After adjustment for body-mass index, hypertension, diabetes, HDL level and parental history of premature myocardial infarction, the increased risk for women in the highest quartile remained statistically significant (relative risk 3·1; 95% confidence interval, 1·1 to 8·3; P=0·03).
Data from the Women's Health Study thus confirm that high sensitivity C-reactive protein and other markers of inflammation are important predictors of cardiovascular risk. As this study used a widely available, standardized commercial assay for high sensitivity C-reactive protein (Dade Behring Inc.), screening for this marker could be practical in many clinical settings. Indeed the US Food and Drug Administration has recently approved use of this high sensitivity C-reactive protein assay for coronary risk screening.
The finding that combining high sensitivity C-reactive protein levels with traditional lipid screening significantly improves risk prediction has several clinical implications. We now know that even those with 'normal' LDL levels can be at increased risk if high sensitivity C-reactive protein levels are elevated. This might indicate a group in whom aggressive primary prevention therapies should be targeted including weight loss, exercise, smoking cessation and diet.
For measurement of high sensitivity C-reactive protein levels to become routine, population distributions of high sensitivity C-reactive protein are required and the magnitude of risk of future coronary events must be known. Table 1 shows the population distribution of high sensitivity C-reactive protein using the FDA approved Dade Behring assay, among a group of over 5000 American men and women without known cardiovascular disease.
Other factors cause significant elevations in high sensitivity C-reactive protein levels. Following an acute infection, high sensitivity C-reactive protein levels may remain elevated for 2-3 weeks and thus an evaluation should be avoided during this time [20] . The use of high sensitivity C-reactive protein for cardiovascular disease prediction may be of limited value in patients with chronic inflammatory conditions, such as systemic lupus erythematosis or rheumatoid arthritis. In most studies, less than 2% of all high sensitivity C-reactive protein levels have been >1·5 mg . dl 1 , a level which may be associated with an alternative inflammatory condition. For most patients, high sensitivity C-reactive protein levels remain relatively stable over long periods of time. Data from the Cholesterol and Recurrent Events (CARE) trial suggests that the correlation coefficient for two samples of high sensitivity C-reactive protein obtained 5 years apart was 0·6, a figure similar or superior to that seen for lipid parameters [21] . Despite these data, two key questions remain: is there a therapy that can reduce levels of high sensitivity C-reactive protein, and will lowering these levels reduce cardiovascular risk? To date these questions have not been directly addressed. However, intriguing data derived from randomized trials of aspirin and statins suggest that the attributable risk reductions in cardiovascular events achieved by these agents may be greater in the presence of elevated high sensitivity C-reactive protein levels [4, 15] . Further, statin therapy appears to reduce high sensitivity C-reactive protein independent of LDL reduction [21] . Thus, the possiblity that high sensitivity C-reactive protein measurement may provide an improved method for selecting those patients who will attain the greatest benefit from aspirin and/or statin therapy is promising. Whether targeted antiinflammatory compounds can acutely stabilize atherosclerotic plaque, and thus provide a novel method of treatment of the acute coronary syndromes, is a major area of future research.
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